Idiopathic Parkinson Disease Clinical Trial
— BiomarParkOfficial title:
Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions
NCT number | NCT05110547 |
Other study ID # | MOREAU 2020 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 27, 2021 |
Est. completion date | April 2023 |
With the aging of the population due to an increase in longevity, the number of people with Parkinson's disease is increasing (166,712 in France, as of December 31, 2015) and the number of patients with motor or cognitive-behavioral disorders is already a major public health challenge (1). In neurodegenerative diseases, the current strategy is to identify the disease early and, if possible, to consider therapeutic measures to slow down the progression of the disease. Classically, when faced with the early stages of Parkinsonism, the investigators differentiate idiopathic Parkinson's disease (IPD) from atypical Parkinsonian syndromes (AP), which include multiple system atrophy (MSA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), for which the prognoses are more severe and the therapies less effective. In the early stage of the disease, when the symptoms are not do no yet differentiate the diseases, the differential diagnosis between IPD and PSP is a real challenge for clinicians (2). Cerebral MRI can help in the diagnosis but is most often only an indicator, as it may be normal in the early stages of the disease (2). The recent emergence of targeted therapies, specific to tauopathies or synucleinopathies, makes it essential to establish a diagnosis as early as possible in order to curb the evolution of the disease (3). The investigators propose here a first study on the analysis of biomarkers of neurodegeneration from lipid metabolism allowing to discriminate IPD and AP from peripheral blood. Two recent studies have provided evidence of the discriminatory character of neurofilament blood testing in the early phases of parkinsonism (4,5). On the other hand, to our knowledge, none of them has studied markers from mitochondrial and peroxisomal metabolism, which could play a key role in the pathophysiology of these diseases (6,7,8,9,10). Our strategy will therefore be to study idiopathic or atypical Parkinsonism subjects with a clearly established diagnosis in a cross-sectional manner, and to identify one or more blood markers of neurodegeneration predictive of IPD or AP, hypothesizing that these markers will be at significantly different levels between the two groups (descriptive analysis). The markers studied will include markers of neurodegeneration, markers of mitochondrial function, peroxisomal function and oxidative stress. The investigators will then study the correlations between these biomarkers and motor scores of disease severity.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | April 2023 |
Est. primary completion date | April 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: For all patients: - Person who was informed of the study and who did not object to inclusion - Age = 18 years - Patient affiliated to national health insurance - Onset of symptoms strictly more than 2 years and less than 7 years ago - Inclusion in the "NS-park" national database - Patient with a recent brain MRI to exclude patients with secondary parkinsonism (vascular parkinson,hydrocephalus at normal pressure) For patients in the "idiopathic Parkinson's disease group" : - Idiopathic Parkinson's disease that is "possible," "probable," or "definite" according to UKPDSBB (UK Parkinson's Disease Society Brain Bank, Hughes et al. 1992) criteria. For patients in the "atypical parkinsonian syndrome" group: - Subjects with a "possible" or "probable" diagnosis of MSA according to the diagnostic criteria of Gilman et al, 2008 - Or Subjects with a "possible" or "probable" diagnosis of AP according to the diagnostic criteria of Hoglinger et al, 2017 - Or Subjects with a "possible" or "probable" diagnosis of CBD according to the diagnostic criteria of Armstrong et al, 2013 Exclusion Criteria: For all patients: - Disability making it impossible for him/her to participate in the trial due to lack of understanding of the information provided to him/her - Patient under guardianship, curatorship or a measure of judicial protection - Patients with any other neurological disease that could bias the results of our study: stroke, brain tumor, other neurodegenerative disease of the nervous system. - Patients with secondary Parkinsonism (iatrogenic, toxic, inflammatory, post-traumatic) - Patients with dyslipidemia receiving lipid-lowering treatment (statins, fibrates, inhibitors of intestinal cholesterol absorption). - Patients with a progressive systemic disease that affects cholesterol metabolism, peroxisomal or mitochondrial function. (Examples: familial hypercholesterolemia, mitochondriopathy, peroxisome biogenesis disorders, etc.) - Patient with a chronic disability making it impossible to collect clinical and cognitive data. - Pregnant or breastfeeding women |
Country | Name | City | State |
---|---|---|---|
France | Chu Dijon Bourgogne | Dijon |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire Dijon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasmatic measurement of 24S and 27 hydroxycholesterol | Markers of neurodegeneration | Baseline | |
Primary | Plasmatic measurement on total leukocytes of the level of complexes 1 to 5 associated | Markers of mitochondrial function | Baseline | |
Primary | Plasma assay of very long chain fatty acids | Markers of peroxisomal function: | Baseline | |
Primary | Plasmatic measurement of ATP production | Markers of mitochondrial function | Baseline | |
Primary | Plasma and leukocyte determination of Octanoyl Coenzyme A | Markers reflecting the relationship between peroxisome and mitochondria: | Baseline | |
Primary | Dosage of uric acid | Markers of oxidative stress | Baseline | |
Primary | Dosage of malondialdehyde (MDA) | Markers of oxidative stress | Baseline | |
Primary | Plasmatic level of neurofilaments (SIMOA) | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04202757 -
Intravenous Plasma Treatment for Parkinson's Disease
|
Early Phase 1 | |
Not yet recruiting |
NCT05103618 -
Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA
|
Phase 2 | |
Completed |
NCT03700684 -
Voice Treatment for Parkinson's Disease
|
N/A | |
Completed |
NCT05027620 -
Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology
|
N/A | |
Completed |
NCT03652363 -
GDNF in ideopathicParkinsons Disease
|
Phase 2 | |
Recruiting |
NCT02960464 -
tDCS for Treatment of Depression in Parkinson's Disease
|
N/A | |
Completed |
NCT05699161 -
Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson
|
Phase 1/Phase 2 | |
Completed |
NCT03944785 -
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
|
||
Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
Terminated |
NCT01215227 -
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
|
Phase 3 | |
Withdrawn |
NCT05832775 -
Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's
|
Phase 1 | |
Active, not recruiting |
NCT02780895 -
Parkinsonian Brain Repair Using Human Stem Cells
|
Phase 1 | |
Recruiting |
NCT01860794 -
Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02393027 -
Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999
|
Early Phase 1 | |
Completed |
NCT02373072 -
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
|
Phase 1 | |
Completed |
NCT02445651 -
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
|
N/A | |
Completed |
NCT00437125 -
Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
|
Phase 4 | |
Completed |
NCT02723396 -
Sleep, Awake & Move - Part I
|
||
Completed |
NCT00599339 -
Transdermal Rotigotine User Surveillance Study
|
||
Suspended |
NCT05471609 -
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
|
Early Phase 1 |